La Renon

What La Renon does

La Renon Healthcare Pvt. Ltd. is an Indian branded-generic pharmaceutical company founded in 2007 in Ahmedabad, focused on chronic disease management across eight specialty therapeutic divisions: Nephrology, Critical Care, CNS, Gastroenterology, Urology, Cardio Metabolic, Respiratory, and Gynaecology. The company manufactures and markets formulations targeting hospitals, ICUs, CCUs, trauma centers, and specialist physicians, and is the first Indian company to focus on early-stage Chronic Kidney Disease, where it claims to serve the highest number of CKD patients in India. Its portfolio includes 60+ CNS products, an expanding nephrology line, and approximately 175 products in pipeline for international markets.

La Renon generates revenue through a specialty marketing model that pairs each therapeutic division with a dedicated sales and marketing team covering India, complemented by direct international distribution to 40+ countries supported by 269 product registrations and 90 applications under evaluation. Vertical integration was deepened in January 2022 via the acquisition of a 51% stake in Enaltec Labs, an API manufacturer with US- and EU-approved facilities. The go-to-market is relationship-driven and field-led, with engagement through medical conferences (ISN, ESICON), KOL webinars on topics such as KDIGO guidelines, and a digital presence on LinkedIn and Facebook.

In FY25 La Renon reported revenue of Rs 1,685 crore (~US$203M) and EBITDA of Rs 356 crore, representing 25% revenue and 30% EBITDA CAGRs over the past decade. Headcount stands at 500+ across divisions. The company has raised institutional capital from Sequoia Capital (2016), A91 Partners (2021), ChrysCapital (April 2024, ~$70M for ~8%), and Creador (December 2025, 7% from Peak XV Partners at a ~$1.26B valuation), with founder Pankaj Singh serving as Chairman & Managing Director.

Name

La Renon

Legal name

La Renon Healthcare Pvt. Ltd.

Website

https://larenon.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

La Renon Healthcare is an Indian branded-generic pharmaceutical company focused on chronic disease management across eight specialty divisions (Nephrology, CNS, Critical Care, Gastroenterology, Urology, Cardio Metabolic, Respiratory, Gynaecology), serving hospitals and specialist physicians in India and 40+ international markets.

Ownership category

akta.pro rank

Product category

Branded Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Branded generic formulations
• Chronic disease management
• Nephrology pharmaceuticals
• Specialty pharma marketing
• Critical care medicines

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D

Revenue model

1. Branded Generic Formulations: Manufacturing and marketing of branded generic pharmaceutical formulations across multiple therapeutic segments including Nephrology, CNS, Critical Care, Gastroenterology, Urology, Cardio Metabolic, Respiratory, and Gynaecology. Products are sold through dedicated marketing teams across India and exported to over 40 countries.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

La Renon Healthcare manufactures and markets branded generic pharmaceutical formulations across eight chronic therapeutic segments — Nephroscience, Critical Care, CNS, Gastroenterology, Urology, Cardio Metabolic, Respiratory, and Gynaecology — to hospitals, ICUs, CCUs, trauma centers, and specialist physicians across India and 40+ international markets. The company is anchored by India's first dedicated Nephrology franchise for early-stage Chronic Kidney Disease patients and operates through division-specific customer-dedicated marketing teams, with API supply from majority-owned Enaltec Labs.

Product overview

La Renon Healthcare is a pharmaceutical company offering branded generic formulations across eight therapeutic divisions: Nephroscience (kidney disease), Critical Care (ICU/anti-infectives), CNS (neurological disorders), Gastroenterology, Urology, Cardio Metabolic (diabetes/hypertension), Respiratory, and Gynaecology. Founded in 2007 and headquartered in Ahmedabad, the company serves the Indian market and exports to over 40 countries with 269 registrations globally. The portfolio includes over 60 CNS products, with approximately 175 products in pipeline. La Renon operates through a specialty marketing process with customer-dedicated marketing teams and comprehensive product portfolios across chronic therapeutic segments.

Differentiator

Problem solved

Functional benefit

Products and services

• Nephroscience Division La Renon's anchor division focusing on chronic kidney disease management with branded generic products for benign prostatic hyperplasia, diabetic kidney disease, hemodialysis, renal medicine, transplant and renal supplements. The basket includes brands such as SILOHIGH, DAPACONIC, IMEG-CKD, LINK-DKD, ANFOE, TACROREN, and SEVLAREN. It is intended for nephrologists and CKD patients across India.
• Critical Care Division Serves ICUs, CCUs, and trauma centers with high-quality anti-infectives and nutraceuticals. The product basket includes antibiotics (AYEBAC, IMIREN, RUAJ, TAZOREN), antivirals (FABIHENZ), GERD management products (VONOQUENCH, ZUROPRAZ), and parenteral nutrition (GLUTAHENZ I.V., LAMINO 10% PLUS). Intended for critical-care intensivists and hospital procurement committees across India.
• CNS Division One of the fastest growing CNS segments in India, addressing epilepsy, Alzheimer's, Parkinson's, stroke, MDD, BPD, schizophrenia, and neuropathic pain. The portfolio includes over 60 products such as BRIVAHENZ, DIVALGRESS, LEVIGRESS, LAREGAB, PBREN, LAPEZIL, LARENTINE, and QUETIGRESS. Intended for neurologists and psychiatrists managing CNS disorders.
• Gastroenterology Division Addresses gastric and liver ailments with branded generic products for acid-related disorders, liver support, and gastrointestinal conditions. Brands include ESOGRESS, RIFAXIGRESS, PANCREHENZ, MESAHENZ, SUCRALHENZ, and LAMINO HEPA. Intended for gastroenterologists and hepatologists.
• Urology Division (Ultracare) Complete basket of branded generic solutions for urological conditions including BPH, kidney stones, and related disorders. Products include ALFUGRESS, TAMGRESS, GUSHOUT, QUROZYME, SEGERA ER, and OCHEK. Intended for urologists managing chronic urological conditions.
• Cardio Metabolic Division Addresses hypertension and diabetes with dedicated branded generic product lines. The basket includes anti-diabetics (DAPAHENZ, EMPASHIELD, LINAHENZ, SITAHENZ, LAFORMIN, IMEZEMIC), anti-hyperlipidemics (BEMZIRE, DISPITOR, IMPUROSE, ROSLAREN), anti-hypertensives (TELMODOR, AZELIREN, SACULYSIN), and anti-coagulants (APIXAGRESS). Intended for endocrinologists, diabetologists, and cardiologists.
• Respiratory Division Addresses respiratory diseases with branded generic products covering a range of respiratory disorders, intended for pulmonologists managing chronic respiratory disease burden in India and international markets.
• Gynaecology Division Addresses women's health from reproductive system to motherhood with first-of-its-kind patent-applied products. Brands include CRAMOSE, DAFADROS, DYDROEASE, E1CHOICE, ELAGOHENZ, FERRONOMIC, and LAMINO She. Intended for gynaecologists and obstetricians managing women's reproductive and pregnancy-related health.

Quantifiable outcome

• Leader in Nephrology serving highest number of CKD patients in India
• +1 more outcomes

Named customers1 record

Segments8 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Enaltec LabscoreStrategic or Co-development PartnerLa Renon acquired a 51% stake in Enaltec Labs, a manufacturer of active pharmaceutical ingredients, in January 2022 at a valuation of Rs 180-200 crore. The deal includes performance-based stake conversion. Enaltec's facilities are approved for regulated markets like the US and Europe, complementing La Renon's formulations business.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Torrent Pharmaceuticals: Indian branded-generic player with strong chronic therapeutic franchises (cardio, CNS, gastro). Comparable therapeutic-area mix and specialty-marketing approach to La Renon.
• Mankind Pharma: One of India's largest domestic-focused branded-generic pharma companies with strong chronic and acute therapy presence. Directly comparable to La Renon given similar India-first GTM, branded-generic model, and growing chronic-disease portfolio.
• Alkem Laboratories: Top-10 Indian pharma with a heavy chronic-disease mix across nephrology, cardiology, CNS and gastroenterology. Closest like-for-like peer given therapeutic-area overlap and Indian domestic-market focus.
• Ipca Laboratories: Mid-sized Indian pharma with branded generics across pain management, cardiovascular, and anti-infectives. Comparable size, product mix, and emerging-market export orientation.
• Glenmark Pharmaceuticals: Indian pharma with branded-generic and API businesses across chronic therapies including dermatology, respiratory, and oncology. Comparable in international footprint and product breadth.

Broad incumbents

• Aurobindo Pharma: Top-5 Indian pharma with dominant API + global generics business, including chronic therapy exposure. Comparable vertical-integration model and international footprint.
• Cipla Limited: One of India's top-3 pharma companies with leadership in respiratory and chronic therapy. Major branded-generic competitor across multiple La Renon divisions.
• Lupin Limited: Large-cap Indian pharma with substantial chronic-disease (cardio, CNS, anti-diabetic) and global generics franchises. Comparable therapeutic mix at much greater scale.
• Dr. Reddy's Laboratories: Leading Indian pharma with strong branded-generic India business and global generics franchise. Overlaps with La Renon on chronic-therapy portfolio and serves as a benchmark for international expansion.
• Zydus Lifesciences (Cadila Healthcare): Large Indian pharma with comprehensive chronic and acute therapy portfolio and strong US generics business. Comparable in nephrology, cardio-metabolic, and CNS exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• Facebookfacebook.com/timeline
• LinkedInlinkedin.com/company/584153
• Xx.com/larenon1

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about La Renon